Taurine Injection

Taurine Injection

Available presentation(s): 10, 30, 100 mL. Verify the exact concentration and total active quantity on the prescription and dispensing label.

Introduction: Taurine is a sulfur-containing amino sulfonic acid involved in bile-acid conjugation, osmoregulation and membrane function. Stand-alone compounded injection has no established general wellness indication or standard dose.

Dosage: No validated standard dose exists for the listed 100 mg/5 mL preparation. Any prescription must specify exact milligram dose, route, dilution/rate, frequency, duration, indication and monitoring. Confirm whether the concentration statement means 20 mg/mL.

Mechanisms of Action: Modulates osmoregulation, calcium handling, membrane stabilisation and inhibitory neurotransmission and contributes to bile salt formation.

Contraindications & Precautions: Use caution in renal impairment, hypotension and electrolyte disorders. Verify formulation, concentration, osmolarity and compatibility. Clinical safety data for standalone injection are limited.

Interactions: Potential additive hypotensive effects are possible. Interactions are otherwise poorly characterised; avoid unvalidated admixtures.

Adverse Reactions / Side Effects: Nausea, headache, dizziness, sedation, hypotension and infusion-site reactions are possible; frequency is unknown.

Pregnancy & Breastfeeding: Insufficient data support elective injectable use during pregnancy or breastfeeding.

Storage: Store under the conditions stated on the Optimus dispensing label and product-specific worksheet. Protect from light where labelled. Do not freeze unless explicitly validated. Maintain cold chain if the label requires refrigeration. Do not use after the assigned beyond-use date or if there is visible particulate matter, precipitation, colour change, loss of container integrity or evidence of improper storage. Once entered, follow the validated in-use time; do not assume a compounded vial is multi-dose.

References

• New Zealand Formulary (NZF), current online edition; product-specific approved data sheets where available; USP Pharmaceutical Compounding—Sterile Preparations; and Optimus Healthcare validated formulation, sterility/endotoxin controls and assigned beyond-use date.
• US FDA. Compounding and the FDA: Questions and Answers. Updated 16 September 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers